RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Alopecia Areata: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Long-term particulate matter exposure and risk of alopecia areata: a nationwide epidemiological study with preliminary in vitro evidence.
Kim Minsu et al., The British journal of dermatology (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42311104/
- 2.
Soluble CD83 reverses alopecia areata via indoleamine 2,3-dioxygenase-mediated regulatory T cell activation.
Wan Sheng et al., The British journal of dermatology (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42397957/
- 3.
Cross-sectional evaluation of TikTok video quality on alopecia areata.
Rosenberg Hilla et al., Dermatology reports (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895110/
- 4.
Investigation of Clinical and Immunological Features of Alopecia Areata With Comorbid Atopic Dermatitis.
Yan Xin et al., Allergy (18 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42894382/
- 5.
Três Caminhos de Investigação para a Alopecia Areata
Deni da Silva Saez, Zenodo (CERN European Organization for Nuclear Research) (16 October 2026)
https://doi.org/10.5281/zenodo.23423122
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
NCT07772492 · Recruiting · Phase 3 · AbbVie
Ages 6 to 17
https://clinicaltrials.gov/study/NCT07772492
- 2.
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
NCT07205159 · Recruiting · Phase 1 · Forte Biosciences, Inc.
Ages 18 to 75
https://clinicaltrials.gov/study/NCT07205159
- 3.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198 · Recruiting · Phase 3 · Eli Lilly and Company
Ages 6 to 17
https://clinicaltrials.gov/study/NCT05723198
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Alopecia Areata
Alopecia areata is an autoimmune condition that causes unpredictable hair loss, ranging from small patches to complete loss of scalp or body hair. It can affect people of any age. Recent years have seen significant research advances, including new JAK inhibitor treatments now approved in several countries.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: Although particulate matter (PM) has been implicated in various systemic and cutaneous diseases, large-scale evidence on whether PM exposure affects the risk of alopecia areata (AA) remains limited. OBJECTIVES: To assess the epidemiological association between long-term PM exposure and incident AA risk with exploration of potential biological mechanisms. METHODS: In the epidemiological study, annual average concentrations of fine (PM2.5) and coarse (PM10) PM were linked to individuals who underwent national health screening between 2006 and 2022, and the risk of incident AA, defined as ≥ 3 outpatient claims with relevant diagnostic codes within a 1-year period, was evaluated. In the preliminary in vitro experiment, human hair outer root sheath (ORS) cells were exposed to varying concentrations of PM10-like fine dust for 24 h. The expression of inflammatory cytokines was evaluated using quantitative real-time polymerase chain reaction, Western blotting and immunofluorescence analyses. RESULTS: Higher long-term PM2.5 and PM10 exposures were associated with increased risk of incident AA [per 10 μg m-3 increase: adjusted hazard ratio (aHR) 1.45, 95% confidence interval (CI) 1.39-1.52 for PM2.5 and aHR 1.32, 95% CI 1.28-1.36 for PM10] with the strongest association for alopecia universalis (per 10 μg m-3 increase: aHR 2.23, 95% CI 1.83-2.63 for PM2.5 and adjusted HR 1.82, 95% CI 1.58-2.07 for PM10). PM10 exposure increased reactive oxygen species generation, the expression of interleukin (IL)-1β, IL-6, IL-8 and IL-15RA, and phosphorylation of p38 and signal transducer and activator of transcription 3 in ORS cells. CONCLUSIONS: This study suggests that ambient PM may be a modifiable environmental risk factor for AA through the activation of selective inflammatory pathways, underscoring the need for public health efforts to reduce PM exposure and potentially mitigate AA risk.
Common Questions
What is Alopecia Areata?
Alopecia areata is an autoimmune condition that causes unpredictable hair loss, ranging from small patches to complete loss of scalp or body hair. It can affect people of any age. Recent years have seen significant research advances, including new JAK inhibitor treatments now approved in several countries.
How many clinical trials are available for Alopecia Areata?
RareWays currently indexes 182 clinical trials for Alopecia Areata, of which 24 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Alopecia Areata come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Alopecia Areata.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.